Cover Image
QR Code

WHO multicentre randomised trial of misoprostol in the management of the third stage of labour.

Background: Postpartum haemorrhage is a leading cause of maternal morbidity and mortality. Active management of the third stage of labour, including use of a uterotonic agent, has been shown to reduce blood loss. Misoprostol (a prostaglandin E1 analogue) has been suggested for this purpose because i...

Full description

Published in:Lancet Vol. 358; no. 9283; pp. 689 - 696
Main Authors: Gülmezoglu AM, Villar J, Ngoc NTN, Piaggio G, Carroli G, Adetoro L, Abdel-Aleem H, Cheng L, Hofmeyr GJ, Lumbiganon P, Unger C, Prendiville W, Pinol A, Elbourne D, El-Refaey H, Schulz KF, Gülmezoglu, A M, Villar, J, Ngoc, N T, Piaggio, G
Format: clinical trial research tables/charts Journal Article
Published: Lancet 9/1/2001
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107068447&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 107068447
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01406736
        LAN
      jtl: Lancet
      issn: 01406736
      maglogo: N
    pubinfo:
      dt: 9/1/2001
      vid: 358
      iid: 9283
      pid: 1297
      pub: Lancet
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        107068447
        107068447
        NLM11551574
        2001104895
        10.1016/s0140-6736(01)05835-4
        NLM11551574
        107068447
      ppf: 689
      ppct: 7
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: WHO multicentre randomised trial of misoprostol in the management of the third stage of labour.
      aug:
        au:
          Gülmezoglu AM
          Villar J
          Ngoc NTN
          Piaggio G
          Carroli G
          Adetoro L
          Abdel-Aleem H
          Cheng L
          Hofmeyr GJ
          Lumbiganon P
          Unger C
          Prendiville W
          Pinol A
          Elbourne D
          El-Refaey H
          Schulz KF
          Gülmezoglu, A M
          Villar, J
          Ngoc, N T
          Piaggio, G
        affil: Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, WHO, Geneva, Switzerland
      sug:
        subj:
          Postpartum Hemorrhage Prevention and Control
          Misoprostol Therapeutic Use
          Oxytocin Therapeutic Use
          Pregnancy
          Labor Stage, Third
          Clinical Trials
          Double-Blind Studies
          Placebos
          Relative Risk
          Confidence Intervals
          Chi Square Test
          Adult
          Female
          Funding Source
          Human
          Adult: 19-44 years
          Female
      ab: Background: Postpartum haemorrhage is a leading cause of maternal morbidity and mortality. Active management of the third stage of labour, including use of a uterotonic agent, has been shown to reduce blood loss. Misoprostol (a prostaglandin E1 analogue) has been suggested for this purpose because it has strong uterotonic effects, can be given orally, is inexpensive, and does not need refrigeration for storage. We did a multicentre, double-blind, randomised controlled trial to determine whether oral misoprostol is as effective as oxytocin during the third stage of labour.Methods: In hospitals in Argentina, China, Egypt, Ireland, Nigeria, South Africa, Switzerland, Thailand, and Vietnam, we randomly assigned women about to deliver vaginally to receive 600 microg misoprostol orally or 10 IU oxytocin intravenously or intramuscularly, according to routine practice, plus corresponding identical placebos. The medications were administered immediately after delivery as part of the active management of the third stage of labour. The primary outcomes were measured postpartum blood loss of 1000 mL or more, and the use of additional uterotonics without an unacceptable level of side-effects. We chose an upper limit of a 35% increase in the risk of blood loss of 1000 mL or more as the margin of clinical equivalence, which was assessed by the confidence interval of the relative risk. Analysis was by intention to treat.Findings: 9264 women were assigned misoprostol and 9266 oxytocin. 37 women in the misoprostol group and 34 in the oxytocin group had emergency caesarean sections and were excluded. 366 (4%) of women on misoprostol had a measured blood loss of 1000 mL or more, compared with 263 (3%) of those on oxytocin (relative risk 1.39 [95% CI 1.19-1.63], p<0.0001). 1398 (15%) women in the misoprostol group and 1002 (11%) in the oxytocin group required additional uterotonics (1.40 [1.29-1.51], p<0.0001). Misoprostol use was also associated with a significantly higher incidence of shivering (3.48 [3.15-3.84]) and raised body temperature (7.17 [5.67-9.07]) in the first hour after delivery.Interpretation: 10 IU oxytocin (intravenous or intramuscular) is preferable to 600 microg oral misoprostol in the active management of the third stage of labour in hospital settings where active management is the norm.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N